BioSpace News Archive

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that the Company’s executive management is scheduled to present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 11:15 a.m. Eastern time.

Arecor Therapeutics plc and TRx Biosciences Limited announced a research collaboration for the formulation development of an oral glucagon-like peptide-1 receptor agonist product.

Sumitomo Pharma Canada, Inc., announced that ORGOVYX®, an oral gonadotropin-releasing hormone receptor antagonist, is now available for prescription in Canada for the treatment of adult patients with advanced prostate cancer.

QurAlis Corporation announced that Kasper Roet, Ph.D., chief executive officer and co-founder, will present a corporate overview at the Stifel 2024 CNS Days being held virtually, March 19-20, 2024.

Mainz Biomed N.V., a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to announce its upcoming participation at the 39th UDH Congress 2024, taking place on March 16th & 17th in Fellbach, Germany.

Black Diamond Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Tonix Pharmaceuticals Holding Corp. will present at the 2024 BIO-Europe Spring Convention being held March 18-20, 2024 in Barcelona, Spain.

X4 Pharmaceuticals, Inc. today announced that it will be reporting financial results for the fourth-quarter and full year ended December 31, 2023 and providing corporate updates on Thursday, March 21, 2024.

89bio, Inc. today announced the initiation of its Phase 3 ENLIGHTEN Program evaluating the efficacy and safety of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH).

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter of 2023 and year-ended 2023.